Taking into account that JAG1 seems to be involved in the genetic susceptibility of MS, its role in the immune system, and the failure of IFN-ß treatment to modulate its function, we propose JAG1 as a new therapeutic target in the treatment of the MS. This evidence concerns the gene IFNA1 and myeloid sarcoma.